{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005260","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.845038+00:00","generated_at":"2026-05-17T15:34:30.858061+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass Q2 net loss $19.9M; CTX-8371 shows deep responses; tovecimig OS readout moves to Q1 2026","bullets":["Net loss Q2 2025 $19.9M ($0.14/share) vs $13.1M ($0.10/share) in Q2 2024; R&D expenses rose 47% to $16.4M.","Tovecimig Ph2/3 BTC trial met primary endpoint (ORR 17.1% vs 5.3%, p=0.031); OS analysis delayed to Q1 2026 due to fewer deaths.","CTX-8371 Ph1: confirmed PR in NSCLC with 100% target lesion reduction and TNBC with >90% reduction; expansion cohorts planned Q4 2025.","CTX-10726 (PD-1 x VEGF-A) showed superior PD-1 inhibition and tumor control vs ivonescimab preclinically; IND filing on track for Q4 2025.","Cash and marketable securities $101M as of June 30, 2025; expected cash runway into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005260","json":"https://secwatch.observer/filing/0001171843-25-005260.json","markdown":"https://secwatch.observer/filing/0001171843-25-005260.md","text":"https://secwatch.observer/filing/0001171843-25-005260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325005260/0001171843-25-005260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325005260/f8k_080925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:34:30.858061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}